C0206473||peptide receptor
C0203608||radionuclide therapy
C1254351||(177)Lu-octreotate
C0024109||pulmonary
C0206754||neuroendocrine tumors
C0936012||analysis
C0206473||peptide receptor
C0203608||radionuclide therapy
C0203608||peptide receptor radionuclide therapy
C0206754||neuroendocrine tumors
C0206754||neuroendocrine tumors
C0024109||pulmonary
C2603343||study
C0600688||toxicity
C0203608||peptide receptor radionuclide therapy
C1254351||(177)Lu-octreotate
C0024109||pulmonary
C0206754||neuroendocrine tumors
C0441800||grade 1-2
C0332293||treated with
C1522577||follow-up
C0599918||nephrotoxicity
C0441800||grade 3
C0920103||hematotoxicity
C0441800||grade 3
C0521982||Treatment response
C0677946||stable disease
C1335499||progressive disease
C0023903||hepatic tumor
C0055633||plasma chromogranin A
C0055633||CgA
C0242656||Disease progression
C0203608||peptide receptor radionuclide therapy
C0162643||treatment failure
C0206754||neuroendocrine tumors
C0012634||disease
C1293130||stabilization
C0920467||disease control
C1254351||(177)Lu-octreotate
C0024109||pulmonary
C0206754||neuroendocrine tumors